<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435588</url>
  </required_header>
  <id_info>
    <org_study_id>22125</org_study_id>
    <nct_id>NCT03435588</nct_id>
  </id_info>
  <brief_title>Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS-guided Fine Needle Biopsy (FNB) Alone in the Diagnosis of Pancreatic Solid Lesions</brief_title>
  <official_title>Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS-guided Fine Needle Biopsy (FNB) Alone in the Diagnosis of Pancreatic Solid Lesions: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the best way to evaluate pancreatic masses is through endoscopic-guided needle
      sampling of the mass to determine the diagnosis by looking at the acquired tissue under a
      microscope. This is done by inserting a small camera (endoscope) through the mouth of the
      patient then advanced to the stomach and using ultrasound guidance a sample of the pancreas
      can be acquired through the stomach. The sampling is usually done with a small needle called
      fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate
      acquisition of cells for proper diagnosis under the microscope, which can lead to need for
      repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site
      evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing
      the endoscopic procedures and evaluates each sampling performed immediately under the
      microscope and can give feedback to the endoscopist until enough cells has been acquired for
      a diagnosis. This method has been shown to increase the ability to diagnose pancreatic cancer
      but is expensive and requires significant amount of resources. New needles called core
      needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells
      but also the entire tissue structure (histology) and has been shown to be also very accurate
      in the diagnosis of pancreatic cancer.

      The purpose of this study is to compare endoscopy-guided biopsy of pancreatic masses with the
      new core needle (FNB), which can obtain more tissue for diagnosis vs. using a traditional
      needle (FNA) with the help of an immediate assessment of the obtained samples under the
      microscope to determine whether enough tissue has been obtained (ROSE). Both approaches have
      been shown to increase the accuracy of diagnosis in solid pancreatic masses but it is unclear
      which one is superior. This is a randomized trial meaning that the participants would either
      undergo biopsy with the new needle or with the traditional needle plus the addition of
      on-site assessment of the obtained samples. The advantage of the new needle is that it is
      easy to implement and likely much cheaper. If the investigators can show in our study that
      the new needles are as accurate as FNA with ROSE then FNB could be implemented across
      hospitals worldwide in an easier and less expensive fashion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Procedures are performed with a linear echoendoscope under conscious sedation. EUS-FNB is performed with a 22 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist. EUS-FNA with ROSE is performed with a 22 gauge FNA needle.
This is a multi-center, randomized, single blinded, non-inferiority, trial comparing EUS-FNB alone to EUS-FNA with ROSE in the diagnosis of solid pancreatic masses. Following consent, patients are randomized, at the time of the procedure, to undergo either EUS-FNB alone or EUS-FNA with ROSE. The randomization sequence will be generated by a computerized randomization scheme using a block size of 10 stratified according to the endoscopist.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as (true positive + true negative)/all samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final diagnosis of malignant pancreatic mass</measure>
    <time_frame>10 months</time_frame>
    <description>Will be based on the following criteria:
Histological evidence of malignancy on the corresponding subsequent surgical specimen
Presence of an unresectable lesion during subsequent surgery
Malignant cytology/pathology on EUS-sampling followed by documented loco-regional progression/development of metastases on follow-up axial imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final diagnosis of benign pancreatic mass</measure>
    <time_frame>10 months</time_frame>
    <description>Will be based on the following criteria:
Surgical pathology or exploration showing the absence of malignancy
Follow-up imaging at &gt; 6 months reporting stability of the pancreatic lesion
Cytological or histopathological diagnosis of benign disease with an appropriate clinical course of disease for minimum of 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic characteristics</measure>
    <time_frame>6 to 12 months of data collection and 3 to 6 months of data analysis.</time_frame>
    <description>sensitivity, specificity, positive and negative predictive value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specimen adequacy</measure>
    <time_frame>6 to 12 months of data collection and 3 to 6 months of data analysis.</time_frame>
    <description>Defined as the proportion of samples in which a final histopathological diagnosis could be made</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of needle passes</measure>
    <time_frame>6 to 12 months of data collection and 3 to 6 months of data analysis.</time_frame>
    <description>Number of times passing the needle for tissue acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural time</measure>
    <time_frame>6 to 12 months of data collection and 3 to 6 months of data analysis.</time_frame>
    <description>Time spent during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of procedure-related adverse events</measure>
    <time_frame>6 to 12 months of data collection and 3 to 6 months of data analysis.</time_frame>
    <description>An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a procedure done, whether or not considered causally related to the procedure.
A serious adverse event is an adverse event occurring during the procedure or any time after the procedure, that fulfills one or more of the following criteria:
Results in death
Is immediately life-threatening
Requires in-patient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability or incapacity
Is a congenital abnormality or birth defect
Is an important medical event that may jeopardize the patient or may require medical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">236</enrollment>
  <condition>Solid Pancreatic Tumor</condition>
  <arm_group>
    <arm_group_label>EUS-FNA with ROSE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EUS-FNA with ROSE is performed with a 22 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-FNB alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS-FNB is performed with a 22 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS</intervention_name>
    <description>Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.</description>
    <arm_group_label>EUS-FNA with ROSE</arm_group_label>
    <arm_group_label>EUS-FNB alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FNA with ROSE</intervention_name>
    <description>Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.</description>
    <arm_group_label>EUS-FNA with ROSE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>FNB alone</intervention_name>
    <description>Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).</description>
    <arm_group_label>EUS-FNB alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Patients referred for EUS evaluation of a definite solid pancreatic mass noted on
             computed tomography(CT)/Magnetic resonance imaging(MRI)/EUS, in which malignancy is
             suspected with no previous histological diagnosis

        Exclusion Criteria:

          -  Age &lt; 18 years, pregnant patients.

          -  Uncorrectable coagulopathy Prothrombin time (PT) &gt;50% of control, Partial
             Thromboplastin time (PTT) &gt;50 sec, or International normalized ratio (INR) &gt;1.5 and/or
             uncorrectable thrombocytopenia platelet count&lt;50, 000109/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yen-I Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yen-I Chen, MD</last_name>
    <phone>514-291-3154</phone>
    <email>yen-i.chen@mail.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clerance Wong</last_name>
      <email>ckw3@ualberta.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Avijit Chatterjee</last_name>
      <email>achatterjee@toh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St-Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christopher Teshima, MD</last_name>
      <phone>416-864-5684</phone>
      <email>TeshimaC@smh.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yen-I Chen, MD</last_name>
      <phone>514-291-3154</phone>
      <email>yen-i.chen@mail.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Klapman JB, Logrono R, Dye CE, Waxman I. Clinical impact of on-site cytopathology interpretation on endoscopic ultrasound-guided fine needle aspiration. Am J Gastroenterol. 2003 Jun;98(6):1289-94.</citation>
    <PMID>12818271</PMID>
  </reference>
  <reference>
    <citation>Gress FG, Hawes RH, Savides TJ, Ikenberry SO, Lehman GA. Endoscopic ultrasound-guided fine-needle aspiration biopsy using linear array and radial scanning endosonography. Gastrointest Endosc. 1997 Mar;45(3):243-50.</citation>
    <PMID>9087830</PMID>
  </reference>
  <reference>
    <citation>Chang KJ, Katz KD, Durbin TE, Erickson RA, Butler JA, Lin F, Wuerker RB. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointest Endosc. 1994 Nov-Dec;40(6):694-9.</citation>
    <PMID>7859967</PMID>
  </reference>
  <reference>
    <citation>Kulesza P, Eltoum IA. Endoscopic ultrasound-guided fine-needle aspiration: sampling, pitfalls, and quality management. Clin Gastroenterol Hepatol. 2007 Nov;5(11):1248-54. Review.</citation>
    <PMID>17981244</PMID>
  </reference>
  <reference>
    <citation>Kandel P, Tranesh G, Nassar A, Bingham R, Raimondo M, Woodward TA, Gomez V, Wallace MB. EUS-guided fine needle biopsy sampling using a novel fork-tip needle: a case-control study. Gastrointest Endosc. 2016 Dec;84(6):1034-1039. doi: 10.1016/j.gie.2016.03.1405. Epub 2016 Mar 24.</citation>
    <PMID>27018087</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Yen-I Chen</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Division of Gastroenterology and Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

